Amgen completes Kai acquisition

THOUSAND OAKS, Calif. — Amgen has completed its acquisition of Kai Pharmaceuticals, a privately held company based in South San Francisco, Calif.

The deal, first announced in April, is valued at $315 million. The deal also includes the acquisition of KAI-4169, an experimental drug Kai is developing for secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. KAI previously reported compelling mid-stage clinical results for KAI-4169 in this indication.

Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.